glp-1 news updates november 2025 drugs can be ‘too easy’ to get online, expert warns Side Effects: Endocrine Society Journals

Retatrutide is currently in Phase 3 clinical trials and is not yet approved by Health Canada or the FDA for obesity treatment

Cost: The list price of Zepbound is $1,086.37 a month, but people with commercial insurance that covers it may pay $25 for a one- or three-month prescription, and people with insurance that doesnt cover it may be eligible to pay as little as $650 a month

Obtaining coverage for Zepbound is limited to its FDA-approved indication

Available online: [DOI] [PubMed] [Google Scholar] 42.Chen P.H., Hibler E

They want something targeted, evidence-informed, and medically supervised

A common ghk-cu stack involves combining it with BPC-157 for accelerated injury repair